MDXH · Mdxhealth SA - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - |
| EPS - Basic | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.03M | $46.80M | $22.38M | $15.50M | $58.50M | $15.95M | - | - |
| Accounts Receivable | $14.68M | $14.44M | $11.09M | $9.36M | $4.58M | $3.77M | - | - |
| Inventory | $6.74M | $3.87M | $2.78M | $2.33M | $1.91M | $2.32M | - | - |
| Accounts Payable | $10.33M | $8.00M | $8.81M | $10.18M | $7.46M | $5.32M | - | - |
| Current Assets | $53.41M | $66.89M | $38.16M | $29.15M | $66.61M | $23.09M | - | - |
| Total Assets | $147.95M | $157.33M | $129.13M | $119.14M | $75.07M | $31.86M | - | - |
| Current Liabilities | $49.53M | $42.66M | $19.52M | $18.28M | $16.43M | $13.02M | - | - |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $160.05M | $142.49M | $121.92M | $109.82M | $28.17M | $26.01M | - | - |
| Stockholders' Equity | ($12.09M) | $14.84M | $7.21M | $9.31M | $46.90M | $5.85M | $19.72M | $52.12M |
| Retained Earnings | ($403.03M) | ($369.51M) | ($331.45M) | ($288.35M) | ($244.30M) | ($215.30M) | - | - |
Cash Flow
| Line item | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | - | - | - | - | - | - | - | - |
| Return on equity | - | - | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 1.08 | 1.57 | 1.95 | 1.59 | 4.05 | 1.77 | - | - |
| Quick ratio | 0.94 | 1.48 | 1.81 | 1.47 | 3.94 | 1.59 | - | - |
| Cash ratio | 0.59 | 1.10 | 1.15 | 0.85 | 3.56 | 1.23 | - | - |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | -12.23 | 10.60 | 17.92 | 12.79 | 1.60 | 5.45 | - | - |
| Liabilities / Assets | 1.08 | 0.91 | 0.94 | 0.92 | 0.38 | 0.82 | - | - |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 105.9% | -22.6% | -80.1% | 701.8% | -70.3% | -62.2% | - |
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing MDxHealth SA against the 5 most active filers in the same SIC group.